| Literature DB >> 26770745 |
Daniel R Beacher1, Adolfo J Ariza2, Mark H Fishbein3, Helen J Binns4.
Abstract
OBJECTIVES: Elevated alanine aminotransferase can heighten concern for the presence of nonalcoholic fatty liver disease in obese children. Guidelines recommend alanine aminotransferase screening of obese children start at the age of 10 years. We examined alanine aminotransferase values routinely obtained for tertiary obesity care among preschool (2-5 years) and school-age children.Entities:
Keywords: Obesity; alanine aminotransferase; children; liver; nonalcoholic fatty liver disease
Year: 2014 PMID: 26770745 PMCID: PMC4607231 DOI: 10.1177/2050312114555211
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Demographic and anthropometric characteristics of children by alanine aminotransferase (ALT) and age groups.
| Total | ALT ≤ 30 IU/L | ALT > 30 IU/L | p value | |
|---|---|---|---|---|
| Ages 2–5 years, n (%) | 73 (100%) | 54 (74%) | 19 (26%) | |
|
| ||||
| Sex | ||||
| Male, n (%) | 33 (45%) | 22 (67%) | 11 (33%) | 0.196[ |
| Female, n (%) | 40 (55%) | 32 (80%) | 8 (20%) | |
| Ethnicity | ||||
| Hispanic, n (%) | 51 (70%) | 39 (75%) | 13 (25%) | 0.873[ |
| Non-Hispanic, n (%) | 22 (30%) | 16 (73%) | 6 (27%) | |
| Insurance | ||||
| Medicaid, n (%) | 59 (81%) | 42 (71%) | 17 (29%) | 0.265[ |
| Private, n (%) | 14 (19%) | 12 (86%) | 2 (11%) | |
|
| ||||
| BMI, kg/m2, median (range) | 24.4 (18.6–36.5) | 24.0 (18.6–36.5) | 27.8 (21.8–32.8) | 0.003[ |
| BMI percentile, median (range)[ | 100 (95.3–100) | 99.9 (95.3–100) | 100 (100–100) | 0.040[ |
| BMI z-score, median (range)[ | 3.4 (1.7–6.2) | 3.3 (1.7–6.2) | 3.6 (2.8–5.9) | 0.016[ |
| %IBW, median (range) | 157.0 (119.3–234.9) | 154.1 (119.3–234.9) | 179.2 (140.0–211.1) | 0.004[ |
| Ages 6–9 years, n (%) | 143 (100%) | 100 (70%) | 43 (30%) | |
|
| ||||
| Sex | ||||
| Male, n (%) | 79 (55%) | 55 (70%) | 24 (30%) | 0.928[ |
| Female, n (%) | 64 (45%) | 45 (70%) | 19 (39%) | |
| Ethnicity | ||||
| Hispanic, n (%) | 102 (71%) | 64 (63%) | 38 (37%) | 0.003[ |
| Non-Hispanic, n (%) | 41 (29%) | 36 (88%) | 5 (12%) | |
| Insurance | ||||
| Medicaid, n (%) | 109 (76%) | 72 (66%) | 37 (34%) | 0.070[ |
| Private, n (%) | 34 (24%) | 28 (82%) | 6 (18%) | |
|
| ||||
| BMI, kg/m2, median (range) | 27.4 (20.5–42.9) | 26.9 (20.5–38.2) | 27.6 (20.8–42.9) | 0.631[ |
| BMI percentile, median (range)[ | 99.4 (95.3–99.9) | 99.4 (95.3–100) | 99.3 (96.3–99.9) | 0.893[ |
| BMI z-score, median (range)[ | 2.5 (1.7–3.1) | 2.5 (1.7–3.1) | 2.5 (1.8–3.1) | 0.912[ |
| %IBW, median (range) | 164.7 (122.1–262.7) | 163.9 (122.1–226.8) | 166.3 (127.6–262.7) | 0.649[ |
| Ages 10–11 years, n (%) | 68 (100%) | 38 (56%) | 30 (44%) | |
|
| ||||
| Sex | ||||
| Male, n (%) | 37 (54%) | 18 (49%) | 19 (51%) | 0.189[ |
| Female, n (%) | 32 (46%) | 20 (64%) | 11 (35%) | |
| Ethnicity | ||||
| Hispanic, n (%) | 54 (79%) | 26 (48%) | 28 (52%) | 0.012[ |
| Non-Hispanic, n (%) | 14 (21%) | 12 (86%) | 2 (14%) | |
| Insurance | ||||
| Medicaid, n (%) | 58 (85%) | 31 (53%) | 27 (47%) | 0.330[ |
| Private, n (%) | 10 (15%) | 7 (70%) | 3 (30%) | |
|
| ||||
| BMI, kg/m2, median (range) | 31.0 (23.6–63.3) | 30.2 (24.3–44.1) | 32.2 (23.6–63.3) | 0.786[ |
| BMI percentile, median (range)[ | 99.2 (95.3–99.9) | 99.1 (95.3–99.8) | 99.2 (96.4–99.9) | 0.693[ |
| BMI z-score, median (range)[ | 2.4 (1.7–3.2) | 2.4 (1.7–2.9) | 2.4 (1.8–3.2) | 0.693[ |
| %IBW, median (range) | 170.2 (132.2–347.9) | 167.9 (132.2–246.4) | 177.0 (132.6–347.9) | 0.630[ |
BMI: body mass index; %IBW: percent ideal body weight for height.
Chi square test.
Fisher’s exact test.
Interpreted using Centers for Disease Control and Prevention (CDC) 2000 Growth References.
Mann–Whitney U test.
Figure 1.Alanine aminotransferase (ALT) values by age group.
Laboratory characteristics of obese children aged 2–11 years by age group.
| Total | Aged 2–5 years | Aged 6–9 years | Aged 10–11 years | p value | |||||
|---|---|---|---|---|---|---|---|---|---|
| n = 284 | n = 73 | n = 143 | n = 68 | ||||||
| n | %[ | n | %[ | n | %[ | n | %[ | ||
| Total cholesterol | 0.259 | ||||||||
| ≥170 mg/dL | 109 | 26 | 22 | 34 | 56 | 43 | 31 | 48 | |
| <170 mg/dL | 151 | 74 | 43 | 66 | 74 | 57 | 34 | 52 | |
| Not evaluated[ | 24 | 8 | 13 | 3 | |||||
| Triglycerides | 0.108 | ||||||||
| ≥75 mg/dL (≤9 years) or ≥90 mg/dL (≥10 years) | 169 | 65 | 35 | 55 | 93 | 70 | 41 | 63 | |
| <75 mg/dL (≤9 years) or <90 mg/dL (≥10 years) | 93 | 35 | 29 | 45 | 40 | 30 | 24 | 37 | |
| Not evaluated[ | 22 | 9 | 10 | 3 | |||||
| LDL | 0.055 | ||||||||
| ≥110 mg/dL | 93 | 36 | 16 | 25 | 48 | 37 | 29 | 45 | |
| <110 mg/dL | 165 | 64 | 48 | 75 | 82 | 63 | 35 | 55 | |
| Not evaluated[ | 26 | 9 | 13 | 4 | |||||
| HDL | 0.160 | ||||||||
| ≤45 mg/dL | 173 | 66 | 40 | 62 | 85 | 63 | 48 | 76 | |
| >45 mg/dL | 88 | 34 | 24 | 38 | 49 | 37 | 15 | 24 | |
| Not evaluated[ | 23 | 9 | 9 | 5 | |||||
| HOMA-IR | 0.007 | ||||||||
| Elevated | 80 | 62 | 12 | 39 | 49 | 69 | 19 | 73 | |
| Normal | 48 | 37 | 19 | 61 | 22 | 31 | 7 | 27 | |
| Not evaluated[ | 156 | 42 | 72 | 42 | |||||
LDL: low-density lipoprotein cholesterol; HDL: high-density lipoprotein cholesterol; HOMA-IR: homeostasis model assessment for insulin resistance.
Column percentage.
Not included in percentages.